September 18, 2014 11:15 PM ET

Company Overview of Karolinska Institutet

Company Overview

Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.

Stockholm,  SE-171-77

Sweden

Founded in 1810

Phone:

46 8 728 64 00

Fax:

46 8 31 11 01

Key Executives for Karolinska Institutet

Vice President
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2014.

Karolinska Institutet Key Developments

Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM

Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM. Venue: EY Headquarters, Stockholm, Sweden. Speakers: Anders Hamsten, President.

Karolinska Institutet Presents at Swedish American Life Science Summit 2013, Aug-22-2013

Karolinska Institutet Presents at Swedish American Life Science Summit 2013, Aug-22-2013. Venue: Box 639, SE-114 11 Stockholm, Sweden. Presentation Date & Speakers: Aug-22-2013, Anders Hamsten, President, Bengt Winblad, Professor of Geriatrics, Kenneth R Chien, Professor of Cardiovascular Research. Aug-23-2013, Johanna Adami, Professor.

AstraZeneca PLC and Karolinska Institutet Intend to Create an Integrated Translational Research Centre

AstraZeneca PLC and Karolinska Institutet announced their intention to create an Integrated Translational Research Centre for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet's site in Stockholm, Sweden. The centre will be set up to conduct preclinical and clinical studies aimed at advancing the understanding of cardiovascular and metabolic disease pathophysiology and assessing new drug targets for AstraZeneca's two biotech units, AstraZeneca Innovative Medicines and Early Development (iMed) and MedImmune. Building on the organisations' longstanding collaboration, the Centre will initially run for a period of five years and will be made up of between 20 and 30 scientists, including a number of AstraZeneca scientists. In addition, AstraZeneca will contribute up to $20 million per annum, and Karolinska Institutet will contribute expertise and facilities. The Centre is expected to be operational by mid-2013.

Similar Private Companies By Industry

Company Name Region
The Lexington Company AB Europe
FTG Forest Technology Group AB Europe
ArcelorMittal SSC AB Europe
Note Torsby AB Europe
Allessa AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Karolinska Institutet, please visit www.ki.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.